Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Kintara Therapeutics Inc (KTRA)

Kintara Therapeutics Inc (KTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers PR Newswire - Mon Mar 23, 6:45AM CDT

Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology

KTRA : 0.2154 (-6.31%)
HURA : 2.68 (-3.60%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives Yolowire - Tue Sep 10, 2024

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 112.89 (+0.29%)
NVS : 147.32 (-0.44%)
RHHBY : 51.2000 (+2.54%)
AZN : 194.81 (-0.50%)
BMRN : 54.15 (-0.86%)
KTRA : 0.2154 (-6.31%)
XBIT : 2.53 (+0.40%)
RKV.VN : 0.110 (unch)
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting PR Newswire - Mon Sep 25, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023 PR Newswire - Thu Aug 17, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the Emerging Growth Conference PR Newswire - Wed Aug 9, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C. PR Newswire - Wed Jul 19, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001 PR Newswire - Wed Jun 28, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)

Barchart Exclusives

This Space Stock Just Proved the Bears Wrong Again—Here's What Comes Next Barchart - 57 minutes ago
AST SpaceMobile’s recent dip highlights how short-term setbacks can obscure long-term progress, especially as major regulatory wins reshape its competitive position. The key question now is execution—not viability. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.